AbbVie’s blockbuster arthritis medication, adalimumab (Humira), now has an FDA-approved competitor: Amgen’s adalimumab-atto, also called Amjevita.
AbbVie’s blockbuster arthritis medication, adalimumab (Humira), now has an FDA-approved competitor: Amgen’s adalimumab-atto, also called Amjevita. The biosimilar has been approved for the following indications:
The approval brings up the count of approved biosimilars in the US market to 4, following last month’s approval of Novartis’ biosimilar to Amgen’s Enbrel.
Serious side effects associated with adalimumab-atto include infections and malignancies. Expected adverse events include infections and injection site reactions, and the product label includes a Boxed Warning on the possibility of infections. The label also includes a warning on the possibility of malignancies in children and adolescents treated with inhibitors of tumor necrosis factor, including adalimumab.
While adalimumab-atto is expected to be sold by Amgen at a discounted price compared with the reference product, patent litigation by AbbVie might hold the product off the market till 2022. “Humira is protected by many patents covering all aspects of its manufacture, formulation and indications and the patents are the result of AbbVie’s investment in biologic innovation and the unique attributes of Humira,” the company told FiercePharma earlier this year. AbbVie has sued Amgen to protect 10 patents on Humira, and has threatened to up that number citing infringement of 51 additional patents.
Analysts however believe that Amgen might make the drug available much earlier, a move that could result in an 18% reduction in sales of Humira, which boasted fourth quarter earnings in 2015 of $3.72 billion and a total annual revenue of more than $14 billion.
It would be interesting to see how Amgen plans to price their product compared to the reference, which costs anywhere between $1800 to $2400 per month without insurance. With a growing national debate over the price of prescription drugs, and pharmacy benefit managers excluding or placing restrictions on the use of more expensive medications when alternatives are available, patients as well as the healthcare industry will be waiting on the price of adalimumab-atto.
Other companies working to develop biosimilar adalimumab products include Novartis, Merck-Samsung Bioepsis, and Baxalta-Momenta.
Beyond Insulin: the Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from the Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More